FeesSafety
Pluang+

$1,000 invested in Eli Lilly 10 years ago is now worth over $20,500, driven by blockbuster diabetes and obesity drugs.

Company Fundamentals
19 Nov 2026, 20:17 WIB
24/7 Wall Street
View Source
Bullish
$1,000 invested in Eli Lilly 10 years ago is now worth over $20,500, driven by blockbuster diabetes and obesity drugs.

Eli Lilly's stock has surged dramatically over the past decade, with a $1,000 investment growing to more than $20,500, thanks mainly to its diabetes and obesity drugs like Mounjaro (tirzepatide) and Zepbound. The company, now valued at over $1.2 trillion, has expanded production to meet high demand and continues to innovate with new drugs such as Kisunla for Alzheimer's and Foundayo, an oral GLP-1 pill. Despite recent price cuts and competition risks, Lilly raised its 2026 revenue guidance and plans new drug filings, maintaining a cautiously optimistic outlook for investors.

Eli Lilly's remarkable growth story over the past decade is underscored by its current market position. On Pluang, Eli Lilly (LLY) trades at USD 1,355.06 as of Nov 20, 2026 01:31 WIB, down 1.99% for the day. The company holds a market cap of $1.23 trillion, close to its 52-week high of $1.44K, with a typical hold time of 95 days among Pluang investors.

More News (LLY)

Eli Lilly's Q3 volume growth beats pricing pressure, raising 2026 revenue guidance with a $1,600 price target.

Eli Lilly's Q3 volume growth beats pricing pressure, raising 2026 revenue guidance with a $1,600 price target.

Eli Lilly reported a 53% volume increase in Q3 despite a 15% drop in realized prices, prompting management to raise 2026 revenue guidance to $91–92 billion. The company's promising drug Retatrutide, currently in Phase 3 trials, supports future growth...

Analyst Insights
Bullish
14 hours ago
Global pharmaceutical market to hit $3.2T by 2035, led by obesity and cancer drug growth amid US tariff shifts

Global pharmaceutical market to hit $3.2T by 2035, led by obesity and cancer drug growth amid US tariff shifts

The global pharmaceutical market is projected to grow from $1.88 trillion in 2026 to $3.20 trillion by 2035, driven mainly by obesity and oncology drugs. The U.S. market, holding 42% of the global share, faces new tariffs linked to pricing deals and ...

Bullish
1 day ago
Anti-obesity drug market to hit $64.96B by 2035, led by Eli Lilly and Novo Nordisk with strong new drug launches.

Anti-obesity drug market to hit $64.96B by 2035, led by Eli Lilly and Novo Nordisk with strong new drug launches.

The global anti-obesity drugs market is projected to grow from USD 8.96 billion in 2026 to USD 64.96 billion by 2035, driven by a CAGR of 24.71%. Eli Lilly and Novo Nordisk dominate the market with blockbuster drugs like Mounjaro, Zepbound, and Wegov...

Bullish
3 days ago
Prelude Therapeutics advances cancer drug trials, reports Q3 2026 loss of $12.5M with cash runway into Q2 2028

Prelude Therapeutics advances cancer drug trials, reports Q3 2026 loss of $12.5M with cash runway into Q2 2028

Prelude Therapeutics reported Q3 2026 financial results with a net loss of $12.5 million and $142.7 million in cash, funding operations into Q2 2028. The company is progressing clinical trials for PRT13722, a selective KAT6A degrader for HR+ breast c...

Company Fundamentals
Bullish
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App